The human papillomavirus vaccine: The promise of cervical cancer prevention

BL Johnston MD1, JM Conly MD2

In February 2007, the National Advisory Committee on Immunization (NACI) – the expert committee that provides the Public Health Agency of Canada with advice relating to immunization – recommended that females between nine and 26 years of age be given the human papillomavirus (HPV) vaccine (1). Within one month, the Government of Canada announced in its federal budget that $300 million would be allocated to the provinces for the HPV vaccine (2). Immunization recommendations are not infrequently associated with a certain amount of controversy, and HPV vaccination is no exception (3). A review of HPV disease and its diagnosis, as well as the evidence supporting the vaccination, will help to put the discussion into context.

Papillomaviruses are nonenveloped, double-stranded, circular DNA viruses. The structural integrity of the capsid proteins is necessary to elicit protective antibodies and has been an important consideration in vaccine development (4). There are two capsid proteins, L1 (major) and L2 (minor), against which neutralizing antibodies may be formed (4). Approximately 100 different types of HPVs have been characterized molecularly (5). They are host specific, and each type is characterized with a distinct histopathological process, ranging from genital and nongenital warts to various forms of invasive cancer (6). The L2 protein is located internally within the capsid. While the anti-L2 antibodies appear to show some cross-reactivity to heterologous HPV types, they are less potent than the anti-L1 antibodies, which appear to be type specific (4).

HPVs infect primitive (undifferentiated) basal keratinocytes, within which they replicate without causing cell damage or death (7). There is no strong signal to the host that a foreign antigen is present, thus allowing the HPV to evade the host immune system for long periods of time. Oncogenic strains are capable of integrating into the host cell genome, leading to persistent infection and potential for malignancy (8). HPV tends to cause cancer at areas known as transformation zones, in which one kind of epithelium contacts and gradually replaces another, explaining its predilection to cause cervical, anal and oropharyngeal cancers (8). Ultimately, however, an immune response is generated in most instances. Animal experiments and natural history studies in humans indicate that this is characterized by a strong local cell-mediated response, followed by the appearance of a serum neutralizing antibody that is protective against reinfection (7). The observed median time to clearance of prevalent infections in various studies has ranged from between four and six months to between one and two years (8). Viral clearance is not often followed by reappearance of the same genotype (8).

Epidemiological studies (9), supported by molecular technology, have provided evidence of the causal role of some HPV types in the development of cervical cancer. Indeed, it has been claimed that HPV represents the first necessary cause of a human cancer. In epidemiological terms, necessary means that the cancer will only develop if the agent is present. Pooled data from 11 case-control studies (10) from nine countries have identified 15 HPV types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82) as carcinogenic (high-risk), and three additional HPV types (types 26, 53 and 66) as probably carcinogenic. HPV-16 and HPV-18 account for 70% of cervical cancers (11). While the type distribution varies somewhat geographically and according to histological type, a vaccine containing the seven most common HPV types (types 16, 18, 45, 31, 52, 33 and 58) would prevent approximately 87% of cervical cancer worldwide with little regional variation (12). Whether such a vaccine would be financially feasible and amenable to evaluation through randomized clinical trials (because of small numbers of cancer associated with non-HPV-16 and non-HPV-18 types) is unknown (12). HPV-16 appears to be the most carcinogenic of the HPVs, with an absolute risk of high-grade intraepithelial neoplasia approaching 40% at five years persistence (8). Despite the prevalence of high-risk HPV types, very few individuals develop premalignant or malignant anogenital disease (5). Apart from smoking, it has been difficult to identify risk factors for invasion that are independent of risks for HPV infection itself (8).

The age-standardized incidence rate for cervical cancer in Canadian females was approximately three of 100,000 females in 2004, down from 15 of 100,000 females in 1978 (13), a reduction that can be attributed largely to cervical cancer screening programs. This compares to approximately 100 of 100,000 females for breast cancer and 40 of 100,000 females for each of colorectal and lung cancers, placing cervical cancer as the sixth most common malignancy in women (13). It has...
been estimated that there will be 377 deaths from cervical cancer in Canadian women in 2007, and 1400 new cases. This compares with 33,000 new cases and 14,000 deaths from lung and breast cancer in Canadian women in 2007. Worldwide, cervical cancer kills an estimated 250,000 women every year, with more than 80% of the 500,000 new cases occurring in the developing world, where cervical cancer is the foremost cause of cancer-related mortality in women (14).

HPV has been associated with a number of other cancers, although the strength of the association is generally not as well established as it is for cervical cancer. These cancers include anogenital and oropharyngeal malignancies (15). Estimates of the attributable fraction of cancer accounted for by HPV, however, demonstrate quite different etiological burdens presented by the virus for the various malignancies. Whereas HPV is responsible for all cervical cancers and 90% of anal cancers in both men and women, it has been estimated to be responsible for only 3% of oral cavity and 12% of oropharyngeal cancers (15). In Canada, it has been estimated that 3200 individuals are diagnosed each year with oral cancer of whom 1100 die (13). By extrapolation, there will be 133 HPV-related oropharyngeal cancer deaths in Canadian men and women in 2007, a cancer for which there is no screening program. Overall, by virtue of its causal role in cervical cancer, HPV is responsible for 5.2% of the world cancer burden – 2.2% in developed countries and 7.7% in developing countries (15).

Obviously, preventing HPV infection would decrease the cancer burden worldwide, with the greatest potential for benefit being in the developed world, and so developing a vaccine against HPV makes inherent good sense. HPV vaccines are preparations of L1 that, when expressed in yeast, assemble into virus-like particles that are structurally very similar to the natural virus. Preclinical experiments revealed that the recombinant virus-like particles were highly immunogenic when combined with an adjuvant (14), and observational studies over the years have suggested that neutralizing antibodies would be protective against new infections (7).

A number of randomized, placebo-controlled trials (16-21) evaluating the safety and efficacy of recombinant HPV vaccine have been published. The majority of these studies have included females between 15 and 26 years of age with few prior sexual partners (six partners or less). The participants may or may not have had prevalent and/or prior HPV infection. Several different outcome measures have been examined, including incident and prevalent HPV infection, the presence of genital warts or cancer, and histological abnormalities predictive of HPV disease. These histological abnormalities include cervical adenocarcinoma in situ, cervical intraepithelial neoplasia (CIN) grades 1 to 3, vulvar intraepithelial neoplasia grades 2 and 3, and vaginal intraepithelial neoplasia grades 2 and 3. Given the long latency period between infection and the appearance of cancer, and the need to treat premalignant lesions (rather than wait for them to evolve into an invasive cancer), surrogate markers of malignancy such as precancerous histological abnormalities have represented an important outcome measure in the clinical trials (4). Grade 1 CIN is not considered to be precancerous, and up to 40% of grade 2 CIN lesions regress spontaneously (22). Grade 3 CIN and adenocarcinoma in situ are the most predictive surrogate markers for invasive cancer potential (22). Studies (16-18,23) have also evaluated the antibody response to immunization, acknowledging that the antibody correlates of protection are unknown.

Quadrivalent (HPV types 6, 11, 16 and 18) and bivalent (HPV types 16 and 18) recombinant vaccines have been studied. HPV types 6 and 11 are responsible for more than 90% of genital wart disease (23). While genital warts are not a cancer precursor, they are the most common of the viral sexually transmitted diseases and place an unquantified burden on the health care system. The quadrivalent vaccine is currently the only one licensed in Canada; licensing of the bivalent product is expected later in 2007. Both the quadrivalent and bivalent vaccines are administered as part of a three-dose series over six months.

In the randomized, controlled clinical trials, two types of analyses have generally been performed. The intention-to-treat (ITT) analysis evaluates outcomes in females with incident or prevalent HPV infection during the vaccination period. The per-protocol analysis (PPA) examines females with no prior HPV infection who remain infection free throughout the first seven months of the trial and have no protocol violations. The ITT situation is thought to reflect the real-life scenario in which sexually active women and girls are exposed to HPV while undergoing immunization, whereas the PPA situation reflects the real-life scenario in which the girls and women have completed the vaccine series before exposure. The results of the ITT analyses allow some sense of vaccine effectiveness, whereas the PPA purely measures vaccine efficacy.

The results of the trials (24), some providing data up to five years following immunization, have been well publicized. While results vary according to the type of analysis performed and outcomes examined, both the bivalent and quadrivalent vaccines have had impressive efficacy (Table 1). In general, the vaccine has been more effective in preventing disease due to HPV-16 than HPV-18, and for protecting against the development of lower grade lesions. These studies are still of insufficient duration to fully quantify the benefit in terms of preventing cancer due to HPV. The benefit was also clearly lower in those who are exposed to HPV before completing the series (ITT) than in those who completed the series before acquiring HPV infection (PPA). The vaccine has been well tolerated in all studies to date (16-21). Whether postmarketing studies or longer-term follow-up will identify unpredicted adverse effects remains to be seen. When serum antibody levels have been measured, neutralizing antibodies remain elevated (17-19,23). In fact, antibody levels tend to be higher in those with vaccine-related immunity than in those with natural immunity (17,18). It is still unknown, however, exactly how long the vaccine is protective in the absence of booster doses. Certainly, for many individuals, exposure to HPV remains a long-term, if not lifelong, risk.

Based on these findings, NACI made its recommendation to immunize females between nine and 26 years of age. The rationale for the younger age is to immunize girls before they become sexually active and are exposed to HPV. Although efficacy trials have not been conducted in this young age group for legal, logistical and ethical reasons, studies looking at the immune response to HPV vaccine in boys and girls between 10 and 15 years of age show higher antibody levels than in females between 16 and 23 years of age (23). Such a ‘bridging efficacy’ study supports the assumption that the vaccine is at least as effective in younger adolescents as in the clinical trial participants. The finding that 20% of 16- to 23-year-old participants in this study were HPV positive at baseline speaks to the need for
Can J Infect Dis Med Microbiol Vol 18 No 4 July/August 2007 231

introducing the vaccine in the early teenage years or even earlier. In their summary statement (1), NACI cited the 2002
Canadian Youth, Sexual Health and HIV/AIDS Study finding that 19% of grade 9 girls reported having had vaginal intercourse at least once. Once they become sexually active, approximately 50% of girls and women acquire HPV infection within three years (5).

Despite the data above, a number of questions remain. How long will protection last? Will boosters be required? Exactly how effective will the vaccine be? Does it make sense to target only one sex in prevention strategies against a sexually transmitted infection? If the goal is cervical cancer prevention, modeling has suggested that immunizing boys would affect its incidence only marginally (4). However, Garnett (25) has argued that the benefit of also immunizing boys could be greater if vaccine uptake in girls is low. Additionally, if oropharyngeal cancer rates continue to increase, with the recognition that it too may be an HPV-related sexually transmitted disease (26), arguments may be made to broaden the vaccine recommendation to include boys. While Canada does not seem to have experienced the political debate observed in the United States around HPV vaccination (3,27), it is unclear whether that will remain the case as vaccine programs roll out across the country. Finally, will HPV-16 and HPV-18 be replaced by other cancer-causing types (22)?

Will this be a cost-effective vaccine? The current approach toward cervical cancer prevention is Papanicolaou cytological screening followed by triage of cases with abnormal cytology toward cervical cancer prevention is Papanicolaou cytological screening followed by triage of cases with abnormal cytology

TABLE 1
Summary of vaccine efficacy (% [95% CI]) in selected human papillomavirus vaccine clinical trials

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Analyses</th>
<th>Persistent infection</th>
<th>Incident infection</th>
<th>CIN-1</th>
<th>≥CIN-2 and CIN-3</th>
<th>ASCUS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quad (16)</td>
<td>266 v</td>
<td>PPA 95.6 (83.8–99.5)</td>
<td>N/A</td>
<td>–</td>
<td>100 (&lt;0–100)</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>263 p</td>
<td>ITT 93.5 (82.5–98.3)</td>
<td>N/A</td>
<td>–</td>
<td>100 (30.8–100)</td>
<td>N/A</td>
</tr>
<tr>
<td>Bival (17)</td>
<td>393 v</td>
<td>PPA 96.0 (75.2–99.9)</td>
<td>94.7 (83.5–98.9)</td>
<td>–</td>
<td>100 (42.4–100)</td>
<td>95.7 (83.5–99.5)</td>
</tr>
<tr>
<td></td>
<td>383 p</td>
<td>ITT 94.4 (78.2–99.4)</td>
<td>88.5 (77.0–95.0)</td>
<td>100 (42.4–100)</td>
<td>100 (7.7–100)</td>
<td>95.7 (83.5–99.5)</td>
</tr>
<tr>
<td>Bival (18)</td>
<td>560 v</td>
<td>PPA 100 (78.6–100)</td>
<td>73.6 (49.7–86.1)</td>
<td>–</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>553 p</td>
<td>ITT 87.5 (64.6–95.6)</td>
<td>67.6 (48.9–79.4)</td>
<td>–</td>
<td>N/A</td>
<td>92.9 (70.0–98.3)</td>
</tr>
<tr>
<td>Quad (19)</td>
<td>277 v</td>
<td>PPA 89 (79–97)</td>
<td>N/A</td>
<td>–</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>275 p</td>
<td>ITT 88 (72–96)</td>
<td>N/A</td>
<td>–</td>
<td>100 (32–100)</td>
<td>N/A</td>
</tr>
<tr>
<td>Quad (20)</td>
<td>5305 v</td>
<td>PPA N/A</td>
<td>N/A</td>
<td>–</td>
<td>98 (86–100)</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>5280 p</td>
<td>ITT N/A</td>
<td>N/A</td>
<td>–</td>
<td>44 (26–58)</td>
<td>N/A</td>
</tr>
<tr>
<td>Quad (21)</td>
<td>2723 v</td>
<td>PPA N/A</td>
<td>N/A</td>
<td>100 (92–100)</td>
<td>CIN-2: 100 (81–100), CIN-3: 100 (78–100)</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>2732 p</td>
<td>ITT N/A</td>
<td>62 (46–74)</td>
<td>–</td>
<td>30 (&lt;0–56), CIN-3: 12 (&lt;0–44)</td>
<td>N/A</td>
</tr>
</tbody>
</table>

ASCUS Atypical squamous cells of undetermined significance; Bival Bivalent; CIN Cervical intraepithelial neoplasia; ITT Intention-to-treat; N/A Not applicable; p Placebo; PPA Per-protocol analysis; Quad Quadrivalent; v Vaccine

REFERENCES